Zai Lab exceeds USD 360 million to introduce multi-target inhibitors to apply for clinical application in China

Text|Pharmaceutical Mission Hills

The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that the TPX-0022 capsule introduced by Zai Lab has been declared for clinical use in China

Screenshot source: CDE official website

According to a press release issued by Zai Lab, TPX-0022 is an oral multi-target kinase inhibitor with a new macrocyclic structure that can inhibit mutations in MET, CSF1R and SRC gene targets

MET is a tyrosine kinase receptor for hepatocyte growth factor (HGF)

SRC is a kinase involved in the MET signaling pathway

It is reported that the inhibition of CSF1R by TPX-0022 allows it to be used as a single agent in a variety of solid tumors or in combination with chemotherapy and immunotherapy as standard therapies

1.

2.

Public information shows that Zai Lab announced in January 2021 that it will further deepen its strategic cooperation with Turning Point Therapeutics, and will obtain the latter's exclusive development and commercialization rights for TPX-0022 in Greater China

Reference materials:

[1] Drug Evaluation Center of China National Medical Products Administration.